Hartman A R, Williams S F, Dillon J J
Department of Medicine, The University of Chicago, IL, USA.
Bone Marrow Transplant. 1998 Sep;22(5):439-43. doi: 10.1038/sj.bmt.1701334.
Randomized, prospective studies comparing BUCY to TBI conditioning regimens for allogeneic bone marrow transplantation have yielded conflicting results. We investigated the overall survival, the disease-free survival and the toxicities of BUCY vs TBI-based regimens by conducting a meta-analysis of all published, randomized, prospective trials comparing these regimens. Five studies were analyzed. We evaluated six endpoints: survival, disease-free survival, veno-occlusive disease (VOD) of the liver, acute GVHD, chronic GVHD, and interstitial pneumonitis. We combined individual study results using a random effects model. Survival and disease-free survival were better with TBI-based regimens than with BUCY, but these differences were not statistically significant (survival odds ratio 1.4, 95% confidence interval 0.9-2.2, P = 0.09; disease-free survival odds ratio 1.2, 95% confidence interval 0.7-2.1, P = 0.44). A power analysis indicated that BUCY was unlikely to have a clinically relevant survival or disease-free survival advantage. The power analysis could not exclude the possibility of such an advantage for TBI-based regimens. A significantly greater incidence of VOD occurred with BUCY (odds ratio 2.5, 95% confidence interval 1.2-5.2, P = 0.02). For the other side-effects, there were no significant differences. We concluded that TBI-based regimens cause less VOD than BUCY and are at least as good for survival and disease-free survival.
比较全身照射(TBI)与白消安/环磷酰胺(BUCY)预处理方案用于异基因骨髓移植的随机前瞻性研究得出了相互矛盾的结果。我们通过对所有已发表的比较这些方案的随机前瞻性试验进行荟萃分析,研究了BUCY与基于TBI的方案的总生存期、无病生存期和毒性。分析了五项研究。我们评估了六个终点:生存期、无病生存期、肝静脉闭塞病(VOD)、急性移植物抗宿主病(GVHD)、慢性GVHD和间质性肺炎。我们使用随机效应模型合并了个体研究结果。基于TBI的方案的生存期和无病生存期优于BUCY,但这些差异无统计学意义(生存优势比1.4,95%置信区间0.9 - 2.2,P = 0.09;无病生存优势比1.2,95%置信区间0.7 - 2.1,P = 0.44)。功效分析表明,BUCY不太可能具有临床相关的生存或无病生存优势。功效分析不能排除基于TBI的方案具有这种优势的可能性。BUCY发生VOD的发生率显著更高(优势比2.5,95%置信区间1.2 - 5.2,P = 0.02)。对于其他副作用,没有显著差异。我们得出结论,基于TBI的方案比BUCY导致的VOD更少,并且在生存和无病生存方面至少同样良好。